What the research found

Researchers examined brain tissue from three groups: people who developed dementia, those who remained cognitively intact, and centenarians who stayed mentally sharp despite having Alzheimer's pathology. Rather than focusing on plaques themselves, they tracked how microglia—the brain's resident immune cells—responded to them.

The key finding centred on a second activation state. When plaques appeared, microglia activated in nearly everyone. But then a critical divergence occurred: in people who developed dementia, microglia shifted into a state that became coupled to tau (a protein associated with neuronal damage), driving cognitive decline. In resilient brains, the same immune shift happened but remained uncoupled from tau—the immune cells activated without triggering downstream damage. Interestingly, resilience took multiple forms: some people's microglia never escalated past an initial controlled response, while others shifted into potentially destructive states yet somehow prevented that transition from causing harm.

Why it matters for you

This reframes what you should actually be measuring and optimising. You cannot yet order your microglia to behave differently, and no drug targeting this pathway exists today. But microglia function depends on the physiological environment they inhabit—your blood glucose regulation, blood pressure, sleep architecture, vascular health, and inflammatory state.

The implications are concrete: the unglamorous interventions already in your MyKine protocol—strength training, sleep tracking, blood pressure monitoring, managing chronic inflammation markers—directly shape the conditions microglia work within. When you track HbA1c, sleep duration, or inflammatory biomarkers, you're monitoring the terrain that determines whether your brain's immune response stays protective or becomes destructive. This isn't about clearing plaques today; it's about building a body and brain environment that supports resilient microglial behaviour now, years before cognitive symptoms would emerge.

The study suggests that cognitive reserve against Alzheimer's-type pathology may depend less on preventing amyloid accumulation and more on ensuring your immune system can respond to it without spiralling into damaging inflammation.

Caveats

• Post-mortem tissue only: This is observational work on donated brains, not a prospective study or intervention trial
• Mechanism inferred, not proven causally: The study identified correlations in tissue state; it has not demonstrated that modifying the identified pathway actually prevents or reverses cognitive decline
• No current translatable target: TREM2 pathway drugs are in development but not clinically available; claims about practical application rest on inference
• Limited sample context: The source does not specify sample sizes, demographic details, or how representative these groups are
• Centenarian selection bias: People who reach 100 with intact cognition despite pathology are by definition a highly selected population; their mechanisms may not generalise